Literature DB >> 16532038

Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation.

M A Weniger1, I Melzner, C K Menz, S Wegener, A J Bucur, K Dorsch, T Mattfeldt, T F E Barth, P Möller.   

Abstract

The suppressors of cytokine signaling (SOCS) are critically involved in the regulation of cellular proliferation, survival, and apoptosis via cytokine-induced JAK/STAT signaling. SOCS-1 silencing by aberrant DNA methylation contributes to oncogenesis in various B-cell neoplasias and carcinomas. Recently, we showed an alternative loss of SOCS-1 function due to deleterious SOCS-1 mutations in a major subset of primary mediastinal B-cell lymphoma (PMBL) and in the PMBL line MedB-1, and a biallelic SOCS-1 deletion in PMBL line Karpas1106P. For both cell lines our previous data demonstrated retarded JAK2 degradation and sustained phospho-JAK2 action leading to enhanced DNA binding of phospho-STAT5. Here, we analysed SOCS-1 in laser-microdissected Hodgkin and Reed-Sternberg (HRS) cells of classical Hodgkin lymphoma (cHL). We detected SOCS-1 mutations in HRS cells of eight of 19 cHL samples and in three of five Hodgkin lymphoma (HL)-derived cell lines by sequencing analysis. Moreover, we found a significant association between mutated SOCS-1 of isolated HRS cells and nuclear phospho-STAT5 accumulation in HRS cells of cHL tumor tissue (P < 0.01). Collectively, these findings support the concept that PMBL and cHL share many overlapping features, and that defective tumor suppressor gene SOCS-1 triggers an oncogenic pathway operative in both lymphomas.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16532038     DOI: 10.1038/sj.onc.1209151

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  97 in total

1.  Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy.

Authors:  Michael R Green; Scott Rodig; Przemyslaw Juszczynski; Jing Ouyang; Papiya Sinha; Evan O'Donnell; Donna Neuberg; Margaret A Shipp
Journal:  Clin Cancer Res       Date:  2012-01-23       Impact factor: 12.531

Review 2.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

Review 3.  [Receptor tyrosine kinases in Hodgkin lymphoma as possible therapeutic targets].

Authors:  C Renné; M L Hansmann; A Bräuninger
Journal:  Pathologe       Date:  2009-09       Impact factor: 1.011

4.  MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma.

Authors:  Aldo M Roccaro; Antonio Sacco; Brian Thompson; Xavier Leleu; Abdel Kareem Azab; Feda Azab; Judith Runnels; Xiaoying Jia; Hai T Ngo; Molly R Melhem; Charles P Lin; Domenico Ribatti; Barrett J Rollins; Thomas E Witzig; Kenneth C Anderson; Irene M Ghobrial
Journal:  Blood       Date:  2009-04-28       Impact factor: 22.113

5.  Human CD30+ B cells represent a unique subset related to Hodgkin lymphoma cells.

Authors:  Marc A Weniger; Enrico Tiacci; Stefanie Schneider; Judith Arnolds; Sabrina Rüschenbaum; Janine Duppach; Marc Seifert; Claudia Döring; Martin-Leo Hansmann; Ralf Küppers
Journal:  J Clin Invest       Date:  2018-06-11       Impact factor: 14.808

Review 6.  Update on the classification of T-cell lymphomas, Hodgkin lymphomas, and histiocytic/dendritic cell neoplasms.

Authors:  Akira Satou; N Nora Bennani; Andrew L Feldman
Journal:  Expert Rev Hematol       Date:  2019-07-31       Impact factor: 2.929

Review 7.  Emerging therapeutic paradigms to target the dysregulated Janus kinase/signal transducer and activator of transcription pathway in hematological malignancies.

Authors:  Tariq I Mughal; Saulius Girnius; Steven T Rosen; Shaji Kumar; Adrian Wiestner; Omar Abdel-Wahab; Jean-Jacques Kiladjian; Wyndham H Wilson; Richard A Van Etten
Journal:  Leuk Lymphoma       Date:  2014-02-17

Review 8.  Molecular pathways: molecular basis for sensitivity and resistance to JAK kinase inhibitors.

Authors:  Sara C Meyer; Ross L Levine
Journal:  Clin Cancer Res       Date:  2014-02-28       Impact factor: 12.531

Review 9.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

Review 10.  [Grayzone lymphoma. Clinical relevance].

Authors:  S Hartmann; M L Hansmann
Journal:  Pathologe       Date:  2010-02       Impact factor: 1.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.